TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30197144

Group type: EXPERIMENTAL
Intervention: 0.6 kg MR
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: 0.8 kg MR
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: 1.1 kg MR
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: ad lib MR
Number of subjects: 96
Study: 27585384

Group type: EXPERIMENTAL
Intervention: Roflumilast 500 μg once daily
Number of subjects: 2354

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2354
Study: 25201722

Group type: EXPERIMENTAL
Intervention: Lung volume reduction surgery (LVRS) plus maximal medical care
Number of subjects: 140

Group type: COMPARATOR
Intervention: Maximal medical care alone
Number of subjects: 140
Study: 22532945

Group type: EXPERIMENTAL
Intervention: Breezy candy (sugar-free) containing zinc gluconate 0.5%, propolis 2%, and a combination of both (zinc 0.25% and propolis 1%)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Regular candy (traditional candy without abrasive particles)
Number of subjects: 75
Study: 20102734

Group type: EXPERIMENTAL
Intervention: Eccentric exercise at 60%, 85%, or 110% of concentric one repetition maxima
Number of subjects: 160

Group type: COMPARATOR
Intervention: Resting control group
Number of subjects: 160
Study: 18652115

Group type: EXPERIMENTAL
Intervention: Eight-Section Brocade practice for 4 months
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Eight-Section Brocade practice for 2 months
Number of subjects: 54
Study: 16025696

Group type: EXPERIMENTAL
Intervention: Moderate-intensity walking intervention (4 times a week for 20 to 30 minutes)
Number of subjects: 173

Group type: COMPARATOR
Intervention: Nonexercise control group
Number of subjects: 173
Study: 12057549

Group type: EXPERIMENTAL
Intervention: Magnesium sulphate
Number of subjects: 10141

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10141
Study: 10687651

Group type: EXPERIMENTAL
Intervention: New polymer hydrogel wound dressing
Number of subjects: 10

Group type: COMPARATOR
Intervention: Leading market hydrocolloid dressing
Number of subjects: 10
Study: 8912780

Group type: EXPERIMENTAL
Intervention: Inhaled methacholine (intervention)
Number of subjects: 0
Study: 1773266

Group type: EXPERIMENTAL
Intervention: Ultrasound
Number of subjects: 40

Group type: COMPARATOR
Intervention: Computed Tomography (CT)
Number of subjects: 40
Study: 6752962

Group type: EXPERIMENTAL
Intervention: Oxprenolol
Number of subjects: 8

Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 8
Study: 31483938

Group type: EXPERIMENTAL
Intervention: Tinnitus Multivariate Integrated Sound Therapy (T-MIST)
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Residual Inhibition Test (RIT)
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Audiometric tinnitus loudness measures
Number of subjects: 148
Study: 26990672

Group type: EXPERIMENTAL
Intervention: Written breastfeeding information in pregnancy and proactive breastfeeding‐focused support phone calls
Number of subjects: 459

Group type: COMPARATOR
Intervention: General birth‐related information with proactive support calls
Number of subjects: 459

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 459

Group type: EXPERIMENTAL
Intervention: Follow-up at 6 months
Number of subjects: 459
Study: 26498242

Group type: COMPARATOR
Intervention: Zolpidem 5 mg
Number of subjects: 13

Group type: COMPARATOR
Intervention: Rilmazafone 1 mg
Number of subjects: 13

Group type: COMPARATOR
Intervention: Triazolam 0.125 mg
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 13
Study: 24367931

Group type: EXPERIMENTAL
Intervention: peg‐IFN or IFN‐α
Number of subjects: 0
Study: 21864613

Group type: EXPERIMENTAL
Intervention: GC1107
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Active comparator (licensed Td vaccine)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: GC1107 and Active comparator
Number of subjects: 40
Study: 19118695

Group type: EXPERIMENTAL
Intervention: Blue-light-filtering IOL (Hoya AF-1 YA-60BB)
Number of subjects: 24

Group type: COMPARATOR
Intervention: UV-filtering IOL (Hoya AF-1 VA-60BB)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Subjective visual impression
Number of subjects: 24
Study: 17652807

Group type: EXPERIMENTAL
Intervention: Liposomal doxorubicin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Anthracyclines
Number of subjects: 0
Study: 15270155

Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Traditional health education (control)
Number of subjects: 240
Study: 11226783

Group type: EXPERIMENTAL
Intervention: Pulsed Q‐switched Nd:YAG laser (ARC GmbH)
Number of subjects: 100
Study: 9400950

Group type: EXPERIMENTAL
Intervention: CDDP/VNR (Cisplatin 100 mg m-2 on day 1 + Vinorelbine 25 mg m-2 i.v. on days 1 and 8 every 21 days for three cycles)
Number of subjects: 100

Group type: COMPARATOR
Intervention: IFO/EPI (Ifosfamide 2.5 g m-2 with mesna on day 1 + High-dose Epirubicin 100 mg m-2 on day 1 every 21 days for three cycles)
Number of subjects: 100
Study: 8423870

Group type: EXPERIMENTAL
Intervention: Intranasal DGAVP treatment
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 2881482

Group type: EXPERIMENTAL
Intervention: Soy polysaccharide (10 g)
Number of subjects: 7
Study: 31449303

Group type: EXPERIMENTAL
Intervention: Muscle energy technique (MET) intervention group
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 55

Group type: COMPARATOR
Intervention: Sham group
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: All groups (including MET, control, and sham)
Number of subjects: 55
Study: 29720719

Group type: EXPERIMENTAL
Intervention: Surgical navigation
Number of subjects: 20

Group type: COMPARATOR
Intervention: No surgical navigation (Control)
Number of subjects: 20
Study: 26720428

Group type: EXPERIMENTAL
Intervention: TEG-guided MTP
Number of subjects: 111

Group type: COMPARATOR
Intervention: CCA-guided MTP
Number of subjects: 111
Study: 24093504

Group type: COMPARATOR
Intervention: Fluticasone furoate/vilanterol (200/25 μg)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Fluticasone furoate/vilanterol (800/100 μg)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Moxifloxacin (400 mg)
Number of subjects: 85
Study: 23084328

Group type: EXPERIMENTAL
Intervention: Active placebos (inducing minor sensations)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Inert placebos (sesame oil)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Active placebos (sesame oil with 0.014% capsaicin)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Placebo-controlled clinical trials (50% chance)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Minor drug onset sensations
Number of subjects: 144
Study: 20702117

Group type: EXPERIMENTAL
Intervention: Statin therapy
Number of subjects: 0
Study: 18973991

Group type: COMPARATOR
Intervention: Olanzapine (5-20 mg/day)
Number of subjects: 546

Group type: EXPERIMENTAL
Intervention: Aripiprazole (15-30 mg/day)
Number of subjects: 546
Study: 15956395

Group type: EXPERIMENTAL
Intervention: Hydatid cyst fluid (HCF)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Native antigen B (AgB)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: AgB8/1 subunit
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: AgB-derived synthetic peptide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: AgB8/2 subunit
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Recombinant cytosolic malate dehydrogenase (EgMDH)
Number of subjects: 0
Study: 12651273

Group type: EXPERIMENTAL
Intervention: rHuEPO
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study: 10565591

Group type: COMPARATOR
Intervention: Stiripentol (STP) in a placebo-controlled trial
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Stiripentol (STP) in an open trial
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Stiripentol (STP) long-term follow-up
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Adverse events reported in the study
Number of subjects: 212
Study: 8907095

Group type: EXPERIMENTAL
Intervention: 2 mg of nicotine polacrilex
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Group behavioral treatment
Number of subjects: 210

Group type: COMPARATOR
Intervention: Placebo gum
Number of subjects: 210

Group type: COMPARATOR
Intervention: Minimal contact plus 2 mg of nicotine gum
Number of subjects: 210
Study: 1863377

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided biopsy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Freehand biopsy
Number of subjects: 0
Study: 6136395

Group type: EXPERIMENTAL
Intervention: 15(R), 15‐methyl‐PGE2 (200 micrograms/day)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Sulfasalazine (2.0 g/day)
Number of subjects: 24
Study: 30639089

Group type: EXPERIMENTAL
Intervention: Postoperative bladder backfilling with 150 mL of normal saline
Number of subjects: 91

Group type: COMPARATOR
Intervention: Control group (drained bladder)
Number of subjects: 91
Study: 30106949

Group type: EXPERIMENTAL
Intervention: Hyperuniform sampling patterns using a single-pixel camera
Number of subjects: 0

Group type: COMPARATOR
Intervention: Regular square patterns
Number of subjects: 0
Study: 26156227

Group type: EXPERIMENTAL
Intervention: Fibrin glue (2 ml Tissucol®; Duploject, Baxter AG) applied on surgical wound before closure
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group (no fibrin glue applied)
Number of subjects: 15
Study: 24252218

Group type: EXPERIMENTAL
Intervention: Best-possible-self mental imagery exercise (15 min writing + 5 min imagery)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Typical day writing and imagery (15 min writing + 5 min imagery)
Number of subjects: 40
Study: 22578446

Group type: EXPERIMENTAL
Intervention: Ranibizumab
Number of subjects: 610

Group type: COMPARATOR
Intervention: Bevacizumab
Number of subjects: 610

Group type: EXPERIMENTAL
Intervention: Discontinuous treatment
Number of subjects: 610

Group type: EXPERIMENTAL
Intervention: Continuous treatment
Number of subjects: 610
Study: 21126958

Group type: EXPERIMENTAL
Intervention: Raltegravir
Number of subjects: 170

Group type: COMPARATOR
Intervention: Enfuvirtide
Number of subjects: 170
Study: 18254225

Group type: EXPERIMENTAL
Intervention: Correction of metabolic disorders and stimulation of endothelial NO‐synthetase
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Correction of metabolic disorders alone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 0
Study: 15974221

Group type: EXPERIMENTAL
Intervention: Cerana glass ceramic inserts
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Beta Quartz glass ceramic inserts
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (bulk-filled with Tetric Ceram without inserts)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both test groups and the control group
Number of subjects: 60
Study: 12908891

Group type: COMPARATOR
Intervention: Control diet (n 5)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Increased ALNA intake (10 g/d, n 4)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Increased EPA+DHA intake (1.5 g/d, n 5)
Number of subjects: 13
Study: 10229728

Group type: EXPERIMENTAL
Intervention: Electrical stimulation for 4 weeks
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no electrical stimulation)
Number of subjects: 40
Study: 8730519

Group type: EXPERIMENTAL
Intervention: Supportive behaviors
Number of subjects: 624

Group type: EXPERIMENTAL
Intervention: Undermining behaviors
Number of subjects: 624

Group type: EXPERIMENTAL
Intervention: Initial supportive behaviors
Number of subjects: 624
Study: 1875415

Group type: EXPERIMENTAL
Intervention: 60 mg/m2 doxorubicin
Number of subjects: 411

Group type: EXPERIMENTAL
Intervention: 320 mg/m2 bisantrene
Number of subjects: 411

Group type: EXPERIMENTAL
Intervention: 14 mg/m2 mitoxantrone
Number of subjects: 411
Study: 6871069

Group type: EXPERIMENTAL
Intervention: Terbutaline sulphate (1 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control
Number of subjects: 10
Study: 29382674

Group type: EXPERIMENTAL
Intervention: Memory Flexibility training (MemFlex)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Psychoeducation control condition
Number of subjects: 0
Study: 26631059

Group type: EXPERIMENTAL
Intervention: WeChat group (received regular reminders and educational messages)
Number of subjects: 224

Group type: COMPARATOR
Intervention: Control group (received conventional management)
Number of subjects: 224
Study: 25582269

Group type: EXPERIMENTAL
Intervention: 10-Hz rTMS applied 5 days per week for 3 weeks to the left dorsolateral prefrontal cortex
Number of subjects: 175

Group type: COMPARATOR
Intervention: Sham rTMS applied similarly
Number of subjects: 175
Study: 23881662

Group type: COMPARATOR
Intervention: Telephone support
Number of subjects: 12256
Study: 20407434

Group type: EXPERIMENTAL
Intervention: AM-only PEG-ELS
Number of subjects: 116

Group type: COMPARATOR
Intervention: PM/AM PEG-ELS
Number of subjects: 116
Study: 18715665

Group type: EXPERIMENTAL
Intervention: Interferon alfa-based antiviral therapies or treatment with polymerase inhibitors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nucleos(t)ide analogues
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pegylated interferon alfa and ribavirin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Initial viral decline with undetectable HCV-RNA at week 4 of therapy (RVR)
Number of subjects: 0
Study: 17508074

Group type: EXPERIMENTAL
Intervention: 10% carbamide peroxide
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: 35% carbamide peroxide
Number of subjects: 55
Study: 14669615

Group type: EXPERIMENTAL
Intervention: prestarium (2‐4 mg/day)
Number of subjects: 42

Group type: COMPARATOR
Intervention: standard combined therapy
Number of subjects: 42
Study: 11071181

Group type: EXPERIMENTAL
Intervention: suplatast tosilate (100 mg three times daily)
Number of subjects: 85

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 85
Study: 9011485

Group type: EXPERIMENTAL
Intervention: Levothyroxine (1.5 micrograms/kg daily)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Iodine (300 micrograms daily)
Number of subjects: 67
Study: 1735253

Group type: EXPERIMENTAL
Intervention: Budesonide 600 micrograms twice daily
Number of subjects: 14
Study: 6321684

Group type: EXPERIMENTAL
Intervention: Trimethoprim/sulfamethoxazole (TMP/SMZ) 320/1600 mg/day
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Trimethoprim/sulfamethoxazole (TMP/SMZ)
Number of subjects: 61
Study: 30935731

Group type: EXPERIMENTAL
Intervention: Intercostal nerve cryoablation
Number of subjects: 20

Group type: COMPARATOR
Intervention: Thoracic epidural analgesia
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 20
Study: 30571234

Group type: EXPERIMENTAL
Intervention: Routine aspirin 75 mg
Number of subjects: 100000

Group type: EXPERIMENTAL
Intervention: Fetal Medicine Foundation screen-and-treat approach
Number of subjects: 100000

Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 100000
Study: 26752495

Group type: EXPERIMENTAL
Intervention: Bupivacaine concentration 0.160 (EC50)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Bupivacaine concentration 0.271 (EC90)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Bupivacaine concentrations
Number of subjects: 52
Study: 24102322

Group type: EXPERIMENTAL
Intervention: Sumatriptan 85 mg/Naproxen sodium 500 mg (S/NS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 22318095

Group type: EXPERIMENTAL
Intervention: Exemestane 25 mg a day for 2 years
Number of subjects: 351

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 351

Group type: EXPERIMENTAL
Intervention: Exemestane
Number of subjects: 351
Study: 18606579

Group type: EXPERIMENTAL
Intervention: Rapid urease test (RUT)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Urea breath test (UBT)
Number of subjects: 31
Study: 17261965

Group type: EXPERIMENTAL
Intervention: Lipoplus (n = 127 patients)
Number of subjects: 256

Group type: COMPARATOR
Intervention: Intralipid (n = 129 patients)
Number of subjects: 256
Study: 15338072

Group type: EXPERIMENTAL
Intervention: Computer program for calculating and drawing QoL-profiles
Number of subjects: 0
Study: 11720459

Group type: EXPERIMENTAL
Intervention: Chemotherapy and best supportive care (BSC)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Best supportive care (BSC) alone
Number of subjects: 113
Study: 9848537

Group type: COMPARATOR
Intervention: Guided Tissue Regeneration (GTR) with polyglycolide/lactide bioabsorbable membrane
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Subpedicle Connective Tissue Graft (SCTG)
Number of subjects: 12
Study: 8083129

Group type: EXPERIMENTAL
Intervention: Preoperative irradiation (single 7-8 Gy fraction administered < 4 h before surgery)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Postoperative irradiation (single 7-8 Gy fraction administered < 48 h after surgery)
Number of subjects: 122
Study: 2521644

Group type: EXPERIMENTAL
Intervention: imipramine 200 mg/day for 3 weeks
Number of subjects: 10

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 10
Study: 1147583

Group type: EXPERIMENTAL
Intervention: Cefazolin 1 g every 6 h for 48 h
Number of subjects: 20

Group type: COMPARATOR
Intervention: Cephalothin 2 g every 6 h for 48 h
Number of subjects: 20
Study: 30640799

Group type: EXPERIMENTAL
Intervention: In-simulation debriefing
Number of subjects: 0

Group type: COMPARATOR
Intervention: Postsimulation debriefing
Number of subjects: 0
Study: 28085888

Group type: EXPERIMENTAL
Intervention: MCO-Ci dialysis
Number of subjects: 48

Group type: COMPARATOR
Intervention: High-flux dialysis
Number of subjects: 48
Study: 25855898

Group type: EXPERIMENTAL
Intervention: Simvastatin
Number of subjects: 650

Group type: EXPERIMENTAL
Intervention: Liposomal siRNA
Number of subjects: 650

Group type: EXPERIMENTAL
Intervention: Simvastatin + Angiopoietin-2 siRNA
Number of subjects: 650

Group type: EXPERIMENTAL
Intervention: Statins (3-hydroxy-3-methyl-glutaryl-CoA reductase inhibitors)
Number of subjects: 650

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 650
Study: 23977178

Group type: EXPERIMENTAL
Intervention: Pamphlet + education intervention
Number of subjects: 317

Group type: EXPERIMENTAL
Intervention: Pamphlet only intervention
Number of subjects: 317

Group type: COMPARATOR
Intervention: Pamphlet (with or without education)
Number of subjects: 317

Group type: EXPERIMENTAL
Intervention: Pamphlet with education
Number of subjects: 317

Group type: EXPERIMENTAL
Intervention: Pamphlet without education
Number of subjects: 317
Study: 21819723

Group type: EXPERIMENTAL
Intervention: Modified thoracoscopic oesophagectomy
Number of subjects: 2

Group type: COMPARATOR
Intervention: Minimally invasive oesophagectomy
Number of subjects: 2
Study: 19516120

Group type: EXPERIMENTAL
Intervention: Surgery
Number of subjects: 1015

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 1015

Group type: EXPERIMENTAL
Intervention: Surgery with AMD and large hemorrhagic lesions (>3.5 MPS disk areas)
Number of subjects: 1015

Group type: EXPERIMENTAL
Intervention: Surgery with AMD and larger hemorrhagic lesions (>16 MPS disk areas) and poor visual acuity (best-corrected visual acuity <=20/1280)
Number of subjects: 1015
Study: 16463197

Group type: EXPERIMENTAL
Intervention: CIFC
Number of subjects: 95

Group type: COMPARATOR
Intervention: CP
Number of subjects: 95
Study: 15174779

Group type: EXPERIMENTAL
Intervention: Zinc supplementation (10 mg of elemental zinc daily)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Control group (supplement without zinc)
Number of subjects: 115
Study: 11394683

Group type: EXPERIMENTAL
Intervention: Consistent goal structure
Number of subjects: 0

Group type: COMPARATOR
Intervention: Varied goal structures
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Consistent spatial arrangement of notes
Number of subjects: 0

Group type: COMPARATOR
Intervention: Varied locations of notes
Number of subjects: 0
Study: 9736819

Group type: EXPERIMENTAL
Intervention: Ultrafiltrate samples from hemodialysis sessions
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: HCV genotype analysis
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Viral load assessment
Number of subjects: 6
Study: 8036962

Group type: EXPERIMENTAL
Intervention: Behavioral weight-loss program
Number of subjects: 186
Study: 2929526

Group type: EXPERIMENTAL
Intervention: Family-based behavioral obesity treatment
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Follow-up after 5 years (small sample of treated children)
Number of subjects: 56
Study: 30903287

Group type: EXPERIMENTAL
Intervention: Transdermal oestradiol 200 μg
Number of subjects: 180

Group type: COMPARATOR
Intervention: Transdermal oestradiol 100 μg
Number of subjects: 180

Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 180
Study: 30073445

Group type: EXPERIMENTAL
Intervention: Mobile app for drug administration
Number of subjects: 74

Group type: COMPARATOR
Intervention: Control scenarios (without app)
Number of subjects: 74
Study: 28363526

Group type: EXPERIMENTAL
Intervention: Ceftazidime/avibactam (2000/500 mg, 2-h infusion) plus metronidazole (500 mg, 60-min infusion)
Number of subjects: 441

Group type: COMPARATOR
Intervention: Meropenem (1000 mg, 30-min infusion)
Number of subjects: 441

Group type: EXPERIMENTAL
Intervention: Ceftazidime/avibactam plus metronidazole
Number of subjects: 441

Group type: COMPARATOR
Intervention: Ceftazidime/avibactam plus metronidazole and Meropenem
Number of subjects: 441
Study: 25315664

Group type: EXPERIMENTAL
Intervention: Eyes with outer retinal tubulation (ORT)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Eyes without outer retinal tubulation (ORT)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Eyes with ORT (multifocal GA lesions)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Eyes without ORT (multifocal GA lesions)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Eyes with ORT (unifocal GA lesions)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Eyes without ORT (unifocal GA lesions)
Number of subjects: 108
Study: 23269782

Group type: EXPERIMENTAL
Intervention: Bilingual education intervention
Number of subjects: 52

Group type: COMPARATOR
Intervention: Attention control group
Number of subjects: 52
Study: 21718775

Group type: EXPERIMENTAL
Intervention: Portulaca oleracea (PO) seeds, 5 g twice daily
Number of subjects: 30

Group type: COMPARATOR
Intervention: Metformin, 1,500 mg/day
Number of subjects: 30
Study: 18640386

Group type: EXPERIMENTAL
Intervention: Oral ERT
Number of subjects: 41

Group type: COMPARATOR
Intervention: Transdermal ERT
Number of subjects: 41